Puma Biotechnology Inc. buy Vassago1
Summary
This prediction ended on 28.09.19 with a price of €10.04. With a performance of -3.39%, the BUY prediction by Vassago1 finished with a loss. Vassago1 has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Puma Biotechnology Inc. | -30.936% | -30.936% | -26.667% | -60.702% |
iShares Core DAX® | 2.821% | -1.953% | 15.071% | 11.862% |
iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% | 40.075% |
iShares Nikkei 225® | 3.687% | -4.221% | 14.286% | 6.629% |
iShares S&P 500 | 3.577% | -2.240% | 25.546% | 38.398% |
According to Vassago1 what are the pros and cons of Puma Biotechnology Inc. for the foreseeable future?
Pros
Cons
Comments by Vassago1 for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Stopped prediction by Vassago1 for Puma Biotechnology Inc.
Puma Biotechnology Inc.
14.09.20
19.09.20
19.09.20
Puma Biotechnology Inc.
24.03.20
04.04.20
04.04.20
Puma Biotechnology Inc.
19.02.20
23.02.20
23.02.20
Puma Biotechnology Inc.
04.02.20
08.02.20
08.02.20
Puma Biotechnology Inc.
28.10.19
09.11.19
09.11.19
Puma Biotechnology Inc.
14.10.19
26.10.19
26.10.19
Puma Biotechnology Inc.
02.09.19
16.09.19
16.09.19
Puma Biotechnology Inc.
21.08.19
01.09.19
01.09.19